53 related articles for article (PubMed ID: 7541235)
1. A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer.
Hickish TF; Smith IE; Nicolson MC; Ashley S; Priest K; Spencer L; Norman A; Middleton G; O'Brien ME
Br J Cancer; 1998 Jun; 77(11):1966-70. PubMed ID: 9667676
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.
de Wit R; Kruit WH; Lamers CH; van 't Veer MB; Luyten AA; van Beurden V; Harteveld M; Planting AS; Schmitz PI; Stoter G; Bolhuis RL; Verweij J
Br J Cancer; 1998 Jun; 77(12):2363-6. PubMed ID: 9649159
[TBL] [Abstract][Full Text] [Related]
3. A comparative review of colony-stimulating factors.
Nemunaitis J
Drugs; 1997 Nov; 54(5):709-29. PubMed ID: 9360058
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic colony-stimulating factors. Uses in combination with standard chemotherapeutic regimens and in support of dose intensification.
Neidhart JA
Cancer; 1992 Aug; 70(4 Suppl):913-20. PubMed ID: 1379115
[TBL] [Abstract][Full Text] [Related]
5. Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification.
Kanz L; Brugger W; Mertelsmann R
Eur J Cancer; 1993; 29A Suppl 5():S23-6. PubMed ID: 8260263
[TBL] [Abstract][Full Text] [Related]
6. Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor.
Leyvraz S; Ketterer N; Perey L; Bauer J; Vuichard P; Grob JP; Schneider P; von Fliedner V; Lejeune F; Bachmann F
Br J Cancer; 1995 Jul; 72(1):178-82. PubMed ID: 7541235
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
[TBL] [Abstract][Full Text] [Related]
8. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
9. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer.
Filip S; Bláha M; Odrázka K; Mericka P; Vávrová J
J Hematother Stem Cell Res; 2000 Feb; 9(1):31-8. PubMed ID: 10738969
[TBL] [Abstract][Full Text] [Related]
10. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
Leyvraz S; Perey L; Rosti G; Lange A; Pampallona S; Peters R; Humblet Y; Bosquée L; Pasini F; Marangolo M
J Clin Oncol; 1999 Nov; 17(11):3531-9. PubMed ID: 10550151
[TBL] [Abstract][Full Text] [Related]
11. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
Tepler I; Cannistra SA; Frei E; Gonin R; Anderson KC; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
J Clin Oncol; 1993 Aug; 11(8):1583-91. PubMed ID: 8101563
[TBL] [Abstract][Full Text] [Related]
12. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.
Ardizzoni A; Venturini M; Crinò L; Sertoli MR; Bruzzi P; Pennucci MC; Mariani GL; Garrone O; Bracarda S; Rosso R
Eur J Cancer; 1993; 29A(5):687-92. PubMed ID: 8385970
[TBL] [Abstract][Full Text] [Related]
13. Intensive combined modality therapy for limited-stage small-cell lung cancer.
Elias AD; Ayash L; Frei E; Skarin AT; Hunt M; Wheeler C; Schwartz G; Mazanet R; Tepler I; Eder JP
J Natl Cancer Inst; 1993 Apr; 85(7):559-66. PubMed ID: 8384264
[TBL] [Abstract][Full Text] [Related]
14. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer.
Arriagada R; Le Chevalier T; Pignon JP; Rivière A; Monnet I; Chomy P; Tuchais C; Tarayre M; Ruffié P
N Engl J Med; 1993 Dec; 329(25):1848-52. PubMed ID: 8247036
[TBL] [Abstract][Full Text] [Related]
15. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
Kritz A; Crown JP; Motzer RJ; Reich LM; Heller G; Moore MP; Hamilton N; Yao TJ; Heelan RT; Schneider JG
Cancer; 1993 Apr; 71(8):2515-21. PubMed ID: 8095854
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
